Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30071194 | 1.00 | CNR2 (0.39) | CNR2CNR1TRPV1PKMP2RX7 | |
| SCHEMBL20154267 | 1.00 | CNR2 (0.39) | CNR2CNR1TRPV1PKMP2RX7 | |
| SCHEMBL29438254 | 0.93 | CNR2 (0.38) | CNR2CNR1TRPV1PKMP2RX7 | |
| SCHEMBL20600383 | 0.93 | CNR2 (0.38) | CNR2CNR1TRPV1PKMP2RX7 | |
| SCHEMBL21875798 | 0.91 | P2RX7 (0.38) | CNR2CNR1TRPV1PKMP2RX7 | |
| SCHEMBL20621805 | 0.91 | P2RX7 (0.38) | CNR2CNR1TRPV1PKMP2RX7 | |
| SCHEMBL29438262 | 0.91 | P2RX7 (0.38) | CNR2CNR1TRPV1PKMP2RX7 | |
| SCHEMBL20600069 | 0.91 | P2RX7 (0.39) | CNR2CNR1TRPV1P2RX7MAPK1 | |
| SCHEMBL29438334 | 0.91 | P2RX7 (0.39) | CNR2CNR1TRPV1P2RX7MAPK1 | |
| SCHEMBL23505822 | 0.90 | PKM (0.39) | CNR2CNR1TRPV1PKMP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505545-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-22 | — | — | US | disclosed |
| CN-109890793-B | Novel anthelmintic quinoline-3-carboxamide derivatives | 拜耳动物保健有限责任公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-3538512-B1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2021-06-16 | — | — | EP | disclosed |
| EP-3538512-B1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2021-06-16 | — | — | EP | disclosed |
| US-20210115026-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-20210115026-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| EP-3538512-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087036-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018087036-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505545-B2 | Anthelmintic quinoline-3-carboxamide derivatives | HRH4, HRH2, H1-5 | CNR2 80/4885CNR1 88/4885TRPV1 695/4885 |
| US-20210115026-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | HRH4, HRH2, HRH1 | CNR2 64/4885CNR1 77/4885TRPV1 683/4885 |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | HRH4, HRH2, H1-5 | CNR2 75/4885CNR1 92/4885TRPV1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.